The pathology of autoimmune haemolytic anaemia.

Sokol, Robert J.; Booker, D J; Stamps, R

doi:10.1136/jcp.45.12.1047

Cited by 104 publications

(87 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean age at the time of diagnosis of our new cohort was 53 years, with peak frequency beyond the age of 70, which agrees with previous data [1,17]. Conversely, unlike our previous series and other reports, we found no female predominance in the present series.…”

Section: Discussionsupporting

confidence: 89%

Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single‐center experience with 60 patients

et al. 2014

View full text Add to dashboard Cite

Warm autoimmune hemolytic anemia (wAIHA) is a rare autoimmune disease with poorly known natural history and management remaining mainly empirical. To better describe the characteristics and outcome of wAIHA in adults, we performed a single-center cohort study of patients diagnosed with wAIIHA from 2001 to 2012 in our center. Sixty patients (50% women) were included, the mean age at the time of wAIHA onset was 54 6 23 years. wAIHA was considered "primary" for 21 patients (35%) and was associated with an underlying disorder in 39 (65%), including mainly lymphoproliferative disorders and systemic lupus. All patients but two needed treatment and received corticosteroids, with an overall initial response rate of 87%. However, 63% of the patients were corticosteroid-dependent and 56% required at least one second-line treatment including mainly rituximab (n 5 19). At the time of analysis, after a mean follow-up of 46 months, 28 patients (47%) were in remission and off treatment and 5 (8%) had died. The presence of an underlying lymphoproliferative disorder was associated with reduced response to corticosteroids and increased need for second-line therapy. In conclusion, in the last decade and compared to a previous series from our center, the rate of secondary wAIHA has increased and the use of rituximab has emerged as the preferred second-line treatment and corticosteroid-sparing strategy; the overall mortality has significantly decreased (8 vs. 18%).Am. J. Hematol. 89:E150-E155,

show abstract

Section: Discussionsupporting

confidence: 89%

Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single‐center experience with 60 patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Warm AIHA is responsible for 48-70% of AIHA cases (Sokol et al, 1992;Gehrs & Friedberg, 2002). By definition, the autoantibodies -the majority of which are in the IgG1 and/or IgG3 subclasses -show maximal binding to RBC at body temperature.…”

Section: Warm Autoimmune Haemolytic Anaemiamentioning

confidence: 99%

“…Cold agglutinin disease or cold agglutinin syndrome represents 16-32% of all AIHA cases (Sokol et al, 1992;Gehrs & Friedberg, 2002). Approximately 90% of CAD cases are mediated by monoclonal antibodies of the IgM class.…”

Section: Cold Agglutinin Diseasementioning

confidence: 99%

See 1 more Smart Citation

Rituximab in the treatment of autoimmune haematological disorders

2008

View full text Add to dashboard Cite

SummaryCurrent treatment regimens for haematological autoimmune diseases are relatively non-selective and are often associated with considerable toxicity. Recently, it has become clear that B cells play a key role in both the development and perpetuation of autoimmunity, suggesting that B-cell depletion could be a valuable treatment approach for patients with autoimmune diseases. This article reviews data supporting the use of rituximab -an anti-CD20 monoclonal antibody that specifically depletes B cells -in four key autoimmune haematological disorders: idiopathic thrombocytopenic purpura (ITP); autoimmune haemolytic anaemia (AIHA); acquired haemophilia; and thrombotic thrombocytopenic purpura (TTP). Although treatment of ITP, AIHA, acquired haemophilia and TTP with rituximab is still relatively uncommon, results from case series and small phase II trials indicate that patients of all ages can respond to rituximab, irrespective of the number or type of prior treatments that they have received. Moreover, patients with these diseases receiving rituximab experienced predominantly mild adverse events, with only a few serious adverse events reported. These data suggest that rituximab provides an effective and well-tolerated alternative treatment option for patients with ITP, AIHA, acquired haemophilia and TTP, many of whom have limited treatment choices.

show abstract

“…Most of these risk factors have been taken from the human literature (Sokol et al 1992(Sokol et al , 1994, and relatively few have been confirmed in dogs. Sulphonamides, cephalosporin, and carprofen have been linked with IMHA (Bloom et al 1988;Trepanier et al 2003;Trepanier 2004;Mellor et al 2005;Lavergne et al 2006).…”

Section: Diagnostic Testingmentioning

confidence: 99%

Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research

Piek

2011

Veterinary Quarterly

View full text Add to dashboard Cite

The pathology of autoimmune haemolytic anaemia.

Cited by 104 publications

References 23 publications

Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single‐center experience with 60 patients

Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single‐center experience with 60 patients

Rituximab in the treatment of autoimmune haematological disorders

Canine idiopathic immune-mediated haemolytic anaemia: a review with recommendations for future research

Contact Info

Product

Resources

About